A Phase 2 interventional study of ixabepilone and ixabepilone + cetuximab in Triple Negative Locally Advanced Non-resectable Breast Cancer and Metastatic Breast Cancer, sponsored by R-Pharm. Completed at 19 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.
Sponsored by R-Pharm · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.
Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2008, is one of 24 in phase 2, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 5
First in 2000; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is close to the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 39 interventional studies. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
15 studies in Breast Neoplasms by R-Pharm: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Breast Neoplasms by R-Pharm, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 6 that started in 2008, is one of 8 in phase 2, and was the 11th registered.
R-Pharm’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing ixabepilone in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing ixabepilone in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among R-Pharm’s 15 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to estimate the response rate of ixabepilone monotherapy, and the combination of ixabepilone plus cetuximab as first-line treatment of female subjects with triple negative (estrogen receptor [ER], progesterone receptor [PR], Human Epidermal Growth Factor Receptor 2 [HER2] negative) locally advanced non-resectable and/or metastatic breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ixabepilone 40 mg/m\^2 every 3 weeks
Drug: ixabepilone
cetuximab 400 mg/m\^2 loading dose then 250 mg/m\^2 weekly + ixabepilone 40 mg/m\^2 every 3 weeks
Drug: ixabepilone + cetuximab
injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria.
Also known as: IXEMPRA, BMS-247550
Drug pages: Ixabepilone · Cetuximab
Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria. Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first. Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria.
Also known as: IXEMPRA, BMS-247550, ERBITUX, BMS-564717
Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])
The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method.
Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)
Number of Participants With Best Overall Response as Assessed With Response Criteria in Solid Tumors (RECIST)
PD = At least a 20% increase in the sum of LD of target lesions in reference to the smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions.
Time frame: Assessed at 6 week intervals for first 12 months from randomization, thereafter every 3 months (to a maximum follow-up for tumor response of 17 months).
Progression Free Survival (PFS)
PFS is defined as the time interval from date of randomization until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.
Time frame: From the date of randomization to date of progression, death, or last tumor assessment (maximum participant PFS of 17 months)
Time to Response
Time to response is defined as the time from the date of start of treatment until measurement criteria are first met for PR or CR (whichever is recorded first). CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the LD of all target lesions with reference to the baseline sum LD. Time to response was estimated using the Kaplan-Meier product-limit method.
Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until CR or PR (maximum participant time to response of 18.3 weeks.)
Duration of Response
Defined as period from the time that measurement criteria are first met for CR or PR until first date of documented PD or death. Estimated using the Kaplan-Meier product-limit method; CI was computed using Brookmeyer and Crowley method. CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of LD of all target lesions with reference to baseline sum LD. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.
Time frame: From the date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 15.6 months)
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs), and AEs Leading to Discontinuation of Study Therapy Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0
AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade (GR) 3=Severe; and GR4=Life-threatening or disabling. Other reasons for death included hepatic failure and respiratory distress.
Time frame: Assessed from the date of first dose until at least 30 days after the last dose of study drug. Median time on ixapebilone therapy was 15 weeks (range: 3-54 weeks for ixabepilone arm; 3-36 weeks for ixabepilone+cetuximab arm)
Number of Participants With Hematology Abnormalities
Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Hemoglobin:GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3:\<8.0-6.5g/dL, GR4:\<6.5g/dL. Platelets:GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3:\<50.0-25.0\*10\^9/L, GR4:\<25.0\*10\^9/L. Absolute Neutrophil Count (ANC):GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3:\<1.0-0.5\*10\^9/L; GR4:\<0.5\*10\^9/L. White blood cell (WBC):GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3:\<2.0-1.0\*10\^9/L; GR4:\<1.0\*10\^9/L. LLN=lower limit of normal.
Time frame: Assessed prior to 1st cycle, at beginning of each cycle, weekly (cetuximab treatment), and every 4 weeks within 30 days after last dose of study drug. Median time on ixapebilone therapy: 15 weeks (range:3-54:ixabepilone arm;3-36:ixapebilone+cetuximab arm)
Number of Participants With Serum Chemistry Abnormalities
Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase: GR1=\>ULN-2.5\*ULN (upper limit of normal); GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4:\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN.
Time frame: Assessed prior to 1st cycle, at beginning of each cycle, weekly (cetuximab treatment), and every 4 weeks within 30 days after last dose of study drug. Median time on ixapebilone therapy: 15 weeks (range:3-54:ixabepilone arm;3-36:ixapebilone+cetuximab arm)
| Milestone | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Started | 40 | 39 |
| Treated | 40 | 37 |
| Completed | 40 | 37 |
| Not completed | 0 | 2 |
| Withdrew: Never treated (not met study criteria) | 0 | 1 |
| Withdrew: Never treated (randomized in error) | 0 | 1 |
PFS is defined as the time interval from date of randomization until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.
| months | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Progression Free Survival (PFS) | 4.1 (3.0 to 4.9) | 4.1 (2.7 to 6.1) |
Time to response is defined as the time from the date of start of treatment until measurement criteria are first met for PR or CR (whichever is recorded first). CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the LD of all target lesions with reference to the baseline sum LD. Time to response was estimated using the Kaplan-Meier product-limit method.
| weeks | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Time to Response | 8.8 (5.1 to 12.0) | 6.5 (5.1 to 18.3) |
The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method.
| percentage of participants | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) | 30.0 (16.6 to 46.5) | 35.9 (21.2 to 52.8) |
Defined as period from the time that measurement criteria are first met for CR or PR until first date of documented PD or death. Estimated using the Kaplan-Meier product-limit method; CI was computed using Brookmeyer and Crowley method. CR: Disappearance of all target and non-target lesions. PR: At least 30% reduction from baseline in the sum of LD of all target lesions with reference to baseline sum LD. PD: At least 20% increase in sum of LD of target lesions in reference to smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall.
| months | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Duration of Response | 4.5 (3.0 to 8.7) | 4.5 (3.4 to 6.9) |
AE: New untoward medical occurrence or worsening of a preexisting medical condition that does not have causal relationship with this treatment. SAE: Untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency/abuse; life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization/prolongs existing hospitalization. Grade (GR) 3=Severe; and GR4=Life-threatening or disabling. Other reasons for death included hepatic failure and respiratory distress.
| participants | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| All Deaths | 8 | 9 |
| Deaths due to Disease Progression | 8 | 7 |
| Deaths due to Other Reasons | 0 | 2 |
| At least one SAE (Any Grade) | 9 | 12 |
| At least one SAE (Grade 3 to 4) | 4 | 11 |
| At least one Related SAE (Any Grade) | 3 | 6 |
| At least one Related SAE (Grade 3 to 4) | 2 | 6 |
| At least one AE (Any Grade) | 40 | 37 |
| At least one AE (Grade 3 to 4) | 21 | 25 |
| At least one Related AE | 37 | 37 |
| At least one Related AE (Grade 3 to 4) | 18 | 22 |
| AEs leading to discontinuation (Any Grade) | 8 | 13 |
| AEs leading to discontinuation (Grade 3 to 4) | 3 | 7 |
Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Hemoglobin:GR1=\<LLN-10.0g/dL; GR2=\<10.0-8.0g/dL; GR3:\<8.0-6.5g/dL, GR4:\<6.5g/dL. Platelets:GR1=\<LLN-75.0\*10\^9/L; GR2=\<75.0-50.0\*10\^9/L; GR3:\<50.0-25.0\*10\^9/L, GR4:\<25.0\*10\^9/L. Absolute Neutrophil Count (ANC):GR1=\<LLN-1.5\*10\^9 /L; GR2=\<1.5-1.0\*10\^9/L; GR3:\<1.0-0.5\*10\^9/L; GR4:\<0.5\*10\^9/L. White blood cell (WBC):GR1=\<LLN-3.0\*10\^9/L; GR2=\<3.0-2.0\*10\^9/L; GR3:\<2.0-1.0\*10\^9/L; GR4:\<1.0\*10\^9/L. LLN=lower limit of normal.
| participants | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| White Blood cell (WBC) GR 1-4 | 33 | 34 |
| WBC GR 3-4 | 13 | 16 |
| Absolute Neutrophil Count(ANC) GR 1-4 (n=39; n=37) | 33 | 31 |
| ANC GR 3-4 (n=39; n=37) | 19 | 18 |
| Platelet Count GR 1-4 (n=39; n=37) | 11 | 4 |
| Platelet Count GR 3-4 (n=39; n=37) | 0 | 0 |
| Hemoglobin GR 1-4 | 29 | 27 |
| Hemoglobin GR 3-4 | 0 | 0 |
PD = At least a 20% increase in the sum of LD of target lesions in reference to the smallest sum LD recorded at or following baseline or unequivocal progression of existing non-target lesion(s) overall; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions.
| participants | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Complete Response | 3 | 0 |
| Partial Response | 9 | 14 |
| Stable Disease | 17 | 12 |
| Progressive Disease | 9 | 10 |
| Never Treated | 0 | 2 |
| Unable to determine | 2 | 1 |
Grading: NCI CTCAE, Version 3.0. GR1=mild, GR2=moderate, GR3=severe, GR4=life threatening or disabling. Normal ranges provided by local laboratory and may also vary by age and sex. Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase: GR1=\>ULN-2.5\*ULN (upper limit of normal); GR2=\>2.5-5.0\*ULN; GR3=\>5.0-20.0\*ULN; GR4:\>20.0\*ULN. Total bilirubin:GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3-10\*ULN, GR4=\>10\*ULN. Creatinine: GR1=\>ULN-1.5\*ULN, GR2=\>1.5-3.0\*ULN, GR3=\>3.0-6.0\*ULN, GR4=\>6.0\*ULN.
| participants | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| Alkaline Phosphatase (ALP) GR 1-4 (n=38; n=35) | 9 | 17 |
| ALP GR 3-4 (n=38; n=35) | 0 | 1 |
| Alanine Aminotransferase (ALT) GR 1-4 (n=39; n=35) | 10 | 18 |
| ALT GR 3-4 (n=39; n=35) | 1 | 0 |
| Aspartate Aminotransferase (AST) GR1-4(n=39; n=35) | 11 | 17 |
| AST GR 3-4 (n=39; n=35) | 1 | 3 |
| Total Bilirubin GR 1-4 (n=39; n=35) | 1 | 3 |
| Total Bilirubin GR 3-4 (n=39; n=35) | 1 | 0 |
| Creatinine GR 1-4 (n=40; n=36) | 3 | 1 |
| Creatinine GR 3-4 (n=40; n=36) | 0 | 0 |
Collected over Assessed from the date of first dose until at least 30 days after the last dose of study drug (Median number of ixabepilone cycles were 5 [range: 1-18 cycles for ixabepilone arm; 1-12 cycles for cetuximab + ixabepilone arm]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixabepilone 40 mg/m^2 | — | 9/40 (22.5%) | 40/40 (100%) |
| Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | — | 12/37 (32.4%) | 37/37 (100%) |
| Event | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/40 | 5/37 |
| TACHYCARDIACardiac disorders | 0/40 | 2/37 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/40 | 2/37 |
| NEUTROPENIABlood and lymphatic system disorders | 0/40 | 2/37 |
| PYREXIAGeneral disorders | 2/40 | 0/37 |
| NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/40 | 0/37 |
| STOMATITISGastrointestinal disorders | 0/40 | 1/37 |
| VOMITINGGastrointestinal disorders | 1/40 | 1/37 |
| ABDOMINAL PAINGastrointestinal disorders | 0/40 | 1/37 |
| CHEST PAINGeneral disorders | 0/40 | 1/37 |
| Event | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 |
|---|---|---|
| ALOPECIASkin and subcutaneous tissue disorders | 23/40 | 13/37 |
| ASTHENIAGeneral disorders | 17/40 | 20/37 |
| NAUSEAGastrointestinal disorders | 13/40 | 19/37 |
| NEUTROPENIABlood and lymphatic system disorders | 18/40 | 19/37 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 17/40 | 17/37 |
| ACNESkin and subcutaneous tissue disorders | 0/40 | 15/37 |
| DRY SKINSkin and subcutaneous tissue disorders | 3/40 | 15/37 |
| DIARRHOEAGastrointestinal disorders | 4/40 | 14/37 |
| VOMITINGGastrointestinal disorders | 15/40 | 11/37 |
| MYALGIAMusculoskeletal and connective tissue disorders | 15/40 | 6/37 |
| Age, Customized(years) | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | Total |
|---|---|---|---|
| Median | 53.0 (29.0 to 75.0) | 50.0 (31.0 to 79.0) | 53.0 (29.0 to 79.0) |
| Age, Customized(participants) | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | Total |
|---|---|---|---|
| < 65 | 35 | 32 | 67 |
| >=65 | 5 | 7 | 12 |
| Sex/Gender, Customized(participants) | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | Total |
|---|---|---|---|
| Female | 40 | 39 | 79 |
| Race/Ethnicity, Customized(participants) | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | Total |
|---|---|---|---|
| White | 39 | 39 | 78 |
| Black/African American | 1 | 0 | 1 |
| Karnofsky Performance Status(participants) | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | Total |
|---|---|---|---|
| 100 | 23 | 23 | 46 |
| 90 | 6 | 5 | 11 |
| 80 | 11 | 10 | 21 |
| Not Reported | 0 | 1 | 1 |
| Setting of Prior Chemotherapy(participants) | Ixabepilone 40 mg/m^2 | Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 | Total |
|---|---|---|---|
| Adjuvant therapy | 28 | 22 | 50 |
| Neo-adjuvant therapy | 20 | 20 | 40 |
| Adjuvant and Neo-adjuvant | 8 | 3 | 11 |
The record gives a start of Jun 2008, a primary completion of Sep 2010 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixabepilone · Cetuximab